30 closest matches · ranked by relevance
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study Population — 20.7; 22.7; 4.5; 4.8 Percentage of participants
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1 — 25.5; 24.6; 21.5; 22.3 Percentage of participants
Invasive Pneumococcal Disease
Primary: Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per…
Vaccines, Pneumococcal
Primary: Percentage of Participants Achieving Predefined Meningococcal C Serum Bactericidal Assay (SBA) Titer of ≥ 1:8, and a Predefined Antibody Level for Diphtheria in 13vPnC…
Vaccines, Pneumococcal
Primary: Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series — 98.2; 98.2; 77.5; 87.1…
Pneumococcal Infections
Primary: Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination — 120; 84; 88; 89 titer
Pneumococcal Vaccines
Primary: Solicited Local Adverse Events (AEs) — 0; 0; 0; 0 events
Vaccines, Pneumococcal
Primary: Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria, Tetanus, Hemophilus Influenza Type b (Hib), Poliomyelitis (Type 1, 2, 3), Pertussis Toxin…
Infections, Streptococcal
Primary: Antibody Concentrations Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) - Primary…
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions (LR) Within 7 Days After Dose 1 — 58.2; 51.3; 26.3; 20.0 Percentage of participants
Pneumococcal Infections
Primary: Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Vaccination in Participants Aged Between 6 to <18 Years — 21.3; 10.6; 10.6; 0.0…
Vaccines, Pneumococcal
Primary: Percentage of Participants Reporting Pre-Specified Local Reactions — 32.1; 30.0; 30.4; 36.7 Percentage of Participants
13-valent Pneumococcal Vaccine · Premature Birth · Immunization
Primary: Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter…
Infections, Streptococcal
Primary: Number of Subjects Reporting Rectal Temperature Above (>) 39.0 Degrees Celsius (°C) — 31; 6; 30; 13 Participants
Vaccines, Pneumococcal
Primary: Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series…
Vaccines, Pneumococcal
Primary: Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series — 94.4; 98.0; 87.3; 92.8…
Vaccines, Pneumococcal
Primary: Percentage of Participants Achieving a Meningococcal C Serum Bactericidal Assay (SBA) Titer ≥1:8 and Predefined Antibody Levels for Pertussis and Haemophilus Influenzae…
Pneumococcal Infections
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1 — 24.9; 25.4; 22.3; 23.7 percentage of participants
Vaccines · Pneumococcal Conjugate Vaccine
Primary: Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Micrograms (mcg)/mL, 1 Month After the Infant Series. — 98.8; 100.0…
Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) Within 1 Month After 13vPnC Vaccination — 0; 7; 0; 0 Percentage…
Pneumococcal Infections
Primary: Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Micrograms (Mcg)/mL, 1 Month After the Infant Series. — 97.0; 97.9…
Vaccines, Pneumococcal Conjugate Vaccine
Primary: Percentage of Subjects Achieving Predefined Antibody Level ≥1:8 for Meningococcal C Serum Bactericidal Assay (SBA) in the 13vPnC Group Relative to 7vPnC Group After 2…
Pneumococcal Vaccine
Primary: Percentage of Participants Achieving a Serotype-specific Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (≥) 0.35 Micrograms Per Milliliter (Mcg/mL)…
13-valent Pneumococcal Vaccine · Immunization · Safety
Primary: Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) 1 Month After Single Dose of 13 Valent Pneumococcal Conjugate (13vPnC) Vaccine…
Pneumococcal Vaccines
Primary: Geometric Mean Concentration (GMC) of Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibodies 1 Month After the Toddler Dose — 5.27; 5.06; 9.63; 8.75 mcg/mL
Pneumococcal Infections
Primary: Percentage of Participants With a New Acquisition of Serotype 6A' (6A + 6C) or 19A Combined 1 Month After the Infant Series to 24 Months of Age — 20.0; 36.0 percentage…
Pneumococcal Infections
Primary: TIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI) — 80.3; 78.6; 58.0…
Infections, Streptococcal · Streptococcus Pneumoniae Vaccines
Primary: Antibody Concentrations Against Pneumococcal Vaccine Serotypes — 2.13; 3.04; 3.24; 1.32 microgram per milliliter
Pneumococcal Infections · Pneumococcal Conjugate Vaccine
Primary: The Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each of the Pneumococcal Serotypes Measured in Cohorts 2, 3 and 4 Compared to IgG…
Infections, Rotavirus
Primary: Concentration of Anti-Protein D Antibodies — 2277.6 EL.U/mL